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BACKGROUND: This study aimed to show the longitudinal use of routinely collected clinical data from history and ultrasound evaluation
of the endometrium in developing an algorithm to predict the risk of endometrial carcinoma for postmenopausal women presenting
with vaginal bleeding.
METHODS: This prospective study collected data from 3047 women presenting with postmenopausal bleeding. Data regarding the
presence of risk factors for endometrial cancer was collected and univariate and multivariate analyses were performed.
RESULTS: Age distribution ranged from 35 to 97 years with a median of 59 years. A total of 149 women (5% of total) were diagnosed
with endometrial carcinoma. Women in the endometrial cancer group were significantly more likely to be older, have higher BMI,
recurrent episodes of bleeding, diabetes, hypertension, or a previous history of breast cancer. An investigator best model selection
approach was used to select the best predictors of cancer, and using logistic regression analysis we created a model, ‘Norwich
DEFAB’, which is a clinical prediction rule for endometrial cancer. The calculated Norwich DEFAB score can vary from a value of 0 to
9. A Norwich DEFAB value equal to or greater than 3 has a positive predictive value (PPV) of 7.78% and negative predictive value
(NPV) of 98.2%, whereas a score equal to or greater than 5 has a PPV of 11.9% and NPV of 97.8%.
CONCLUSION: The combination of clinical information with our investigation tool for women with postmenopausal vaginal bleeding
allows the clinician to calculate a predicted risk of endometrial malignancy and prioritise subsequent clinical investigations.
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Postmenopausal bleeding refers to any genital tract bleeding in a
postmenopausal woman, other than the expected bleeding that
occurs in women taking sequential hormone replacement therapy
(HRT). Because postmenopausal bleeding is the most common
symptom of endometrial cancer, when postmenopausal bleeding
occurs, clinical evaluation is indicated (Goldstein et al, 2001).
Approximately 10% (range 1–25%) of women presenting with
postmenopausal bleeding will be diagnosed with endometrial
carcinoma (Gambrell et al, 1978; Alberico et al, 1989; Iatrakis et al,
1997). Endometrial atrophy is the most common cause of genital
tract bleeding among postmenopausal women (Iatrakis et al,
1997). Endometrial hyperplasia and polyps are also common
causes.
Two different forms of endometrial carcinoma have been
identified. Type-I cancers have an endometrioid histology and
account for 70–80% of endometrial carcinomas. They are
associated with unopposed oestrogen stimulation of the endome-
trium and tend to arise in women with obesity, hyperlipidaemia,
and other hyper-oestrogenic conditions. Type-II cancers have a
non-endometrioid histology and arise in women who are less likely
to have the clinical associations seen in type-I cancers (Bokhman,
1983). Several risk factors such as obesity, tamoxifen use,
increasing age, hypertension, diabetes, and unopposed use of
exogenous oestrogens are strongly associated with increased risk
of type-I endometrial cancer (Persson et al, 1989; Soler et al, 1999;
Cohen, 2004; Lachance et al, 2006; Friberg et al, 2007; Lucenteforte
et al, 2007; Renehan et al, 2008). Early menarche and late
menopause have also been implicated due to prolonged oestrogen
stimulation of the endometrium. Nulliparity as an isolated risk
factor does not appear to increase the risk of endometrial cancer,
although due to the high frequency of anovulatory cycles there
may be an association in women with subfertility (Chen and Berek,
2008). Hereditary non-polyposis colorectal cancer is a significant
but rare risk factor, with descendants of an affected family member
carrying a theoretical 50% lifetime risk of endometrial cancer
(Aarnio et al, 1995).
Currently, controversy exists as to whether transvaginal
ultrasonography or endometrial biopsy should be used as the
initial diagnostic step for clinical evaluation of women presenting
with postmenopausal bleeding (Goldstein et al, 2001). In addition,
decisions made about the most appropriate investigations that
need to be performed, are not always guided by clinical history.
The few studies that attempt to include information gained from
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sclinical history to predict the risk of endometrial carcinoma are
too small to develop a predictive model (Weber et al, 1999;
Bachmann et al, 2003).
The aim of our study was to use routinely collected clinical data
from history and ultrasound evaluation of the endometrium to
develop an algorithm to predict the risk of endometrial carcinoma
in women presenting to secondary care with postmenopausal
vaginal bleeding.
MATERIALS AND METHODS
Participants
This is a prospective cohort study, conducted at a gynaecological
oncology centre in the United Kingdom, between February 2006
and May 2009. All postmenopausal women presenting with vaginal
bleeding to the postmenopausal bleeding clinic were included.
Menopause was defined as at least 12 months of spontaneous
amenorrhoea. Premenopausal women were not included in the
study as there is no standard threshold for endometrial thickness
in this group that is considered abnormal. Other groups of women
seen at the clinic that were excluded from the study included
asymptomatic women with an incidental finding of increased
endometrial thickness on imaging and asymptomatic women with
abnormal endometrial cytology found on cervical smear.
Procedures
All women presenting with vaginal bleeding underwent trans-
vaginal ultrasound scanning to evaluate the endometrium. The
double-wall endometrial thickness was measured in an anterio-
posterior dimension from one basalis layer to the other. In keeping
with departmental guidelines, when endometrial thickness was
measured to be less than 5mm no further investigations were
performed as evidence suggests a low probability of cancer below
this threshold (Karlsson et al, 1995; Smith-Bindman et al, 1998).
For the purpose of the study, we considered all women with
endometrial thickness less than 5mm as negative for endometrial
cancer.
Women with endometrial thickness equal to or greater than
5mm had endometrial sampling performed using an endometrial
Pipelle device. Hysteroscopic evaluation of the endometrium with
biopsy under a general anaesthetic was performed if Pipelle biopsy
was not possible or did not yield sufficient tissue for histological
diagnosis. A hysteroscopy was also performed for any woman re-
appearing at the clinic for a second time with a recurrent episode
of bleeding.
Clinical risk factors – data collection
The clinic collects routine data regarding essential clinical
information and presence of risk factors for endometrial cancer
using a pre-designed proforma. Data extracted from these forms
for this study were age of the patient at presentation, body mass
index (BMI), use of HRT, presence of hypertension and diabetes,
previous history of breast cancer, and use of tamoxifen.
Endometrial thickness measured on ultrasound scan and results
of histology when performed were also recorded. We excluded data
regarding parity as we consider that it is the frequency of
anovulatory cycles that increases the risk of endometrial cancer
and not nulliparity per se. Data from 90% of the patients were
collected prospectively and only in 10% of the cases was it
collected retrospectively.
We also attempted to assess whether the bleeding pattern of
women had any predictive value in the histological outcome. The
amount of bleeding was characterised as spotting, light (¼less
than a period), and heavy (¼like a period or worse). Any event
lasting less than 7 days was defined as a single bleeding episode.
Recurrent episodes were defined as any bleeding episode lasting
7 or more days or two or more separate bleeding events within the
last 12 months.
All the data analysed were collected as part of the routine
investigations and treatment. The patients were investigated
according to established evidence-based departmental guidelines.
Statistical analysis
The distributions of continuous variables were not symmetric. To
test for normality, the Shapiro-Wilk W-test was used, as was the
q-q plot to investigate normality graphically (results not shown).
There was no evidence to suggest that data were normally
distributed, hence in the descriptive statistics for continuous
variables, we report median and inter-quartile range. To avoid
inflating the type-I error rate, loss of power, residual confounding,
and bias, continuous predictor variables were not categorised (Del
Priore et al, 1997; Austin and Brunner, 2004; Royston et al, 2006).
To test any differences we used a non-parametric Wilcoxon rank
sum (Mann–Whitney) test. Binomial exact methods were used to
calculate 95% confidence intervals (CIs) of the proportions and to
test any differences in the proportions observed. w
2-test was used
after checking the expected assumptions. An investigator best
model selection approach was used to select the best predictors of
cancer in the multiple logistic regression model as opposed to
machine-led step-wise regression, which is not advisable (Hurvich
and Tsai, 1990; Derksen and Keselman, 1992). Selection of
predictor variables was performed by using the likelihood ratio
test after estimation of the nested models by adding and
eliminating variables one at a time. The likelihood ratio test is
similar to using model selection indices such as Akaike informa-
tion criterion (AIC) or Bayesian information criterion (BIC). All
analyses were performed using STATA software, version 10.1 SE
(Stata Corporation, College Station, TX, USA).
RESULTS
Demographics
During a 39-month interval, 3047 women were investigated for
postmenopausal vaginal bleeding. Age distribution ranged from
35 to 97 years with a median of 59 years. A total of 149 women (5%
of total) were diagnosed with endometrial carcinoma. Women with
all types of endometrial cancer were included in this group. The
remaining 2898 women (95%) were included in the non-cancer
group for the purposes of the study.
Clinical risk factors
The results of univariate analysis to assess for correlation between
individual clinical characteristics and development of endometrial
cancer are given in Table 1. Women in the endometrial cancer
group were significantly older (median 64 vs 59 years; Po0.0001)
and had higher BMI (31 vs 28kgm
 2, Po0.0001) than women
without cancer. They were more likely to have diabetes
(Po0.0001) and hypertension (P¼0.001). The duration of use of
HRT did not appear to increase the risk of endometrial cancer
(P¼0.243). The women in the endometrial cancer group were
significantly more likely to have a previous history of breast cancer
(P¼0.025). However, the duration of use of tamoxifen in the
breast cancer group did not appear to increase the risk of
endometrial cancer (P¼0.091). The amount of vaginal bleeding
did not appear to be associated with increased risk of endometrial
cancer (P¼0.289). Recurrent episodes of vaginal bleeding were
significantly more likely to be associated with endometrial cancer
than a single bleeding event (Po0.0001). Endometrial thickness on
ultrasound scan was significantly higher in women with endo-
metrial cancer (14.9 vs 4.6mm; Po0.0001).
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sAs a result of the statistical analysis the investigating team
determined that the factors considered best predictors of
endometrial malignancy were age, BMI, presence of diabetes, and
endometrial thickness (P-value o0.0001, 0.038, 0.030, and
o0.0001, respectively). Recurrent episodes of vaginal bleeding
were significantly more likely to be associated with endometrial
cancer than a single episode (odds ratio 3.93, 95% CI 2.48–6.23),
taking into account diabetic status, age, BMI, and endometrial
thickness (Table 2).
Predictive model: Norwich DEFAB
We have created a model with regard to predicting the odds of
endometrial carcinoma in postmenopausal women presenting with
vaginal bleeding. We are calling this tool DEFAB, which is a
clinical prediction rule based on Diabetes, Endometrial thickness,
Frequency of bleeding, Age, and BMI. In the DEFAB criteria,
presence of diabetes in a patient scores 2; endometrial thickness
X14mm scores 1; recurrent episodes of bleeding scores 4; age
X64 years scores 1; and BMIX31kgm
 2 scores 1. If a criterion is
absent, then the score is 0. The calculated Norwich DEFAB score
can vary from a value of 0–9. The scores were arrived at by taking
account of the predictive odds of cancer from the adjusted model.
The overall sensitivity, specificity, and likelihood ratio for each
Norwich DEFAB cut-off point are shown in Table 3. Table 3 also
shows the overall proportion (percentage) of the total numbers
that have been correctly classified by Norwich DEFAB in each
category. The difference in the odds for malignancy predicted by a
Norwich DEFAB value equal to or greater than 3 and equal to or
greater than 5 was 4.53 and 6.06, respectively. Table 4 shows the
Table 1 Basic characteristics of the population. Univariate comparison
Factors Cancer, n¼149 (5%) No cancer, n¼2898 (95%) P-value
Age (years) 64 (59–72) 59 (54–67) o0.0001
a
BMI (kgm
 2) 31 (27–36) 28 (25–32) o0.0001
a
Diabetes
Yes 25 (17%, 11–24%) 158 (5%, 5–6%) o0.0001
b
No 124 (83%, 76–89%) 2740 (95%, 94–95%)
Hypertension
Yes 56 (38%, 30–46%) 741 (26%, 24–27%) 0.001
b
No 93 (62%, 54–70%) 2157 (74%, 73–76%)
HRT duration (years) 9 (4–20) 5 (2–10) 0.243
a
Breast cancer
Yes 16 (11%, 6–17%) 178 (6%, 5–7%) 0.025
b
No 133 (89%, 83–94%) 2720 (94%, 93–95%)
Tamoxifen use (years) 4.5 (2–8) 3 (2–5) 0.091
a
Amount of bleeding*
Spotting 39 (27%, 20–35%) 611 (21%, 20–23%)
Light 80 (55%, 46–63%) 1620 (57%, 55–59%) 0.289
b
Heavy 27 (18%, 13–26%) 614 (22%, 20–23%)
Frequency of bleeding*
Single 36 (24%, 18–32%) 1541 (53%, 52–55%) o0.0001
b
Recurrent 112 (76%, 68–82%) 1345 (47%, 45–48%)
Endometrial thickness (mm) 14.9 (11.0–21.0) 4.6 (3.0–7.8) o0.0001
a
Abbreviations: BMI¼body mass index; HRT¼hormone replacement therapy. Values are median (inter-quartile range), number (percent, 95% CI of percent).
aTwo-sample Wilcoxon rank sum test (Mann–Whitney test).
bw
2-Test. *Percentages worked on less numbers from the overall due to missing values.
Table 2 Adjusted predictors of cancer (odds ratio) from the best model
that fits the data well
Predictors of cancer
Odds ratio
(95% confidence interval) P-value
Age (years) 1.04 (1.02–1.06) o0.0001
BMI (kgm
 2) 1.03 (1.00–1.06) 0.038
Endometrial thickness (mm) 1.15 (1.13–1.18) o0.0001
Frequency of bleeding
Single episode 1
Recurrent episode 3.93 (2.48–6.23) o0.0001
Diabetes
Yes 1.92 (1.07–3.45) 0.030
No 1
Abbreviation: BMI¼body mass index.
Table 3 Overall sensitivity, specificity, and correct classification for each
DEFAB cut-off point
Cut-point Sensitivity Specificity
Correctly
classified LR (+) LR ( ) d-OR
(4¼0) 100.00% 0.00% 4.88% 1.000 —
(4¼1) 95.95% 25.57% 29.00% 1.289 0.159 8.11
(4¼2) 88.51% 44.70% 46.84% 1.601 0.257 6.23
(4¼3) 81.76% 50.28% 51.81% 1.644 0.363 4.53
(4¼4) 79.05% 52.56% 53.86% 1.667 0.399 4.18
(4¼5) 67.57% 74.43% 74.09% 2.642 0.436 6.06
(4¼6) 43.24% 92.38% 89.98% 5.673 0.614 9.24
(4¼7) 16.22% 96.92% 92.98% 5.258 0.865 6.08
(4¼8) 8.78% 99.27% 94.86% 12.071 0.919 13.13
(4¼9) 3.38% 99.90% 95.19% 32.510 0.967 33.62
(49) 0% 100.0% 95.12% 1.000 —
ROC Area¼0.769, 95% CI (0.730–809). LR (+)¼Likelihood ratio (+ve)¼Pr
(+ve|+ve)/Pr (+ve| ve). LR ( )¼Likelihood ratio ( ve)¼Pr ( ve|+ve)/Pr
( ve| ve). d-OR¼diagnostic odds ratio¼LR (+)/LR ( ).
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predictive value (NPV), and receiver operating characteristics
(ROC) area for Norwich DEFAB cut-off values equal to or greater
than 3 and 5. A Norwich DEFAB value equal to or greater than 3
achieved a sensitivity of 81.9% (95% CI, 74.7–87.7%), specificity of
50.1% (95% CI, 48.2–51.9%), and an ROC area of 0.660 (95% CI,
0.627–0.692). For a Norwich DEFAB cut-off score equal to or
greater than 5, sensitivity, specificity, and ROC area were 67.8%
(95% CI, 59.6–75.2%), 74.1% (95% CI, 72.5–75.7%), and 0.710
(95% CI, 0.671–0.748), respectively.
The accuracy of a test depends on how well the test separates the
group being tested into those with and without the disease in
question. The area under the ROC curve measures accuracy. An
area of 1 represents a perfect test and an area of 0.5 represents a
worthless test. The overall predictive ability for the Norwich
DEFAB measured by the area under the ROC curve was 0.7694
(Figure 1). Our clinical prediction rule would be considered to be
of ‘fair accuracy’ at separating women with cancer from women
without cancer, according to the traditional academic point
system: fail, poor, fair, good, excellent.
DISCUSSION
The main objective of the diagnostic evaluation of women with
postmenopausal vaginal bleeding is exclusion of malignancy.
Women with postmenopausal uterine bleeding may be assessed
initially with either endometrial biopsy or transvaginal ultrasono-
graphy. Initial evaluation does not require performance of both
tests (ACOG Committee Opinion No 440, 2009). Currently, with
respect to mortality, morbidity, and quality-of-life end points,
there are insufficient data to comment as to whether transvaginal
ultrasonography or endometrial biopsy is most effective for initial
evaluation of this group of women. Which approach is used
initially depends on the risk of the patient and the nature of the
clinician’s practice (Goldstein et al, 2001). As it is not clear which
approach for evaluation of the endometrium is more effective, we
attempted in this study to find a way of discriminating patients at
low and high risk of endometrial cancer. This individualised risk
prediction will allow clinicians to make more efficient use of the
available diagnostic resources and simultaneously minimise false-
negative results from various investigations.
Currently, information gained from the clinical history is not
taken into account when performing risk assessment for
postmenopausal women with vaginal bleeding. The optimal
assessment of women with postmenopausal bleeding would be to
stratify the population of women into high-risk and low-risk
groups on the basis of history and ultrasound scan results. The
low-risk group would undergo endometrial biopsy and the higher
risk would undergo immediate visualisation and biopsy of the
endometrium for definitive tissue diagnosis.
We propose an algorithm (Norwich DEFAB) for predicting the
risk of endometrial carcinoma on the basis of the odds of cancer
from multiple logistic regression analysis for individual women
presenting with postmenopausal vaginal bleeding. Norwich DEFAB
provides a quantitative assessment of the risk of malignancy
incorporating patient characteristics of diabetes, ultrasound scan
assessment of endometrial thickness, frequency of bleeding, age,
and BMI.
We propose that introduction of the Norwich DEFAB probabil-
istic model in clinical practice can improve the accuracy and
efficiency of diagnostic work-up. For women at high risk of
malignancy further diagnostic evaluation is indicated even if the
initial tests were negative. Depending on prior evaluation, a
combination of repeat endometrial biopsy or hysteroscopy should
be pursued.
For example, a 70-year-old woman with a BMI of 35, who
presents with a 2-week episode of vaginal bleeding, would have a
Norwich DEFAB score of 6 (age¼1, BMI¼1, recurrent
bleeding¼4) if no other risk factors are present. According to
current practice, if endometrial thickness measures less than 5mm
on transvaginal ultrasound scan, no further testing would be
offered to the patient; only if the patient has an ultrasound scan
showing endometrial thickness greater than 5mm, would an
endometrial Pipelle biopsy be performed. However, as this patient
is at increased risk of having endometrial malignancy according to
the DEFAB score, we suggest that further testing, including
endometrial biopsy, should be offered regardless of endometrial
thickness measurement. If the biopsy does not show any
abnormality, we suggest hysteroscopic evaluation of the
endometrium (Chart 1).
We recommend that a Norwich DEFAB cut-off score equal to or
greater than 3 should be used to consider further investigations. At
this cut-off point, high sensitivity (81.9%) is achieved. Although
specificity appears to be low (50.1%), this is not clinically
important when considering that the primary objective is not to
miss cases of malignancy. A trade-off between sensitivity and
specificity is observed as the Norwich DEFAB score increases. For
a Norwich DEFAB score of 5 sensitivity decreases to 67.8% and
specificity increases to 74.1%.
When developing the predictive model in our study, we analysed
type-I and type-II endometrial cancer cases in the same group.
Although there are publications showing that women with type-II
endometrial cancer have different clinical characteristics when
compared with women with type-I endometrial cancer, recent
evidence suggests that there is no difference in the age of diagnosis
of both types of the disease. Also, obesity increases the risk of both
type-I and type-II endometrial cancer (Bjorge et al, 2007). In
addition, no difference was observed in the results of the predictive
model when investigated in women with type-I cancer separately.
This was not surprising as we had a small number of women with
Table 4 Sensitivity, specificity, PPV, and NPV for DEFAB cut-offs of X3
and X5
DEFAB score X3,
estimate (95% CI)
DEFAB score X5,
estimate (95% CI)
Sensitivity 81.9% (74.7–87.7%) 67.8% (59.6–75.2%)
Specificity 50.1% (48.2–51.9%) 74.1 (72.5–75.7%)
ROC area 0.660 (0.627–0.692) 0.710 (0.671–0.748)
PPV 7.78% (6.50–9.21%) 11.9% (9.77–14.2%)
NPV 98.2% (97.4–98.8%) 97.8% (97.1–98.4%)
Abbreviations: CI¼confidence interval; NPV¼negative predictive value; PPV¼
positive predictive value; ROC¼receiver operating characteristic curve.
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Figure 1 Area under the ROC curve for DEFAB scores.
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include all endometrial cancers, as it is not possible to distinguish
between the two types at initial presentation of the patient, when
applying the algorithm.
One of the limitations of this study is the fact that cases where
endometrial thickness measurement was less that 5mm were
attributed to genital tract atrophy and no further investigation was
performed. This was a pragmatic study based on the current
practice in our unit where transvaginal ultrasonography is used as
the initial tool to select patients who require further investigation.
This practice is based on the recommendations and evidence
mentioned above (ACOG Committee Opinion No 440, 2009). To
evaluate the applicability of our findings in other populations,
external validation of the predictive model at different cut-off
points is required. External validation is also required before
introduction of this model in clinical practice.
In conclusion, we have shown that incorporation of clinical
information with an initial investigation tool into a risk prediction
model allows assessment of the probability of the disease, which
may be used to refine subsequent investigations and treatment
strategies. This not only has benefit in the process of disease
detection but also may result in improved efficiency of care.
It is not yet certain whether application of the Norwich
DEFAB in clinical practice will have an effect on the
prognosis for endometrial cancer. This should be a topic for
further research.
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